Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 149.00
-3.00 (-1.97%)
At close: Feb 6, 2026
Noile-Immune Biotech Revenue
Noile-Immune Biotech had revenue of 1.00M JPY in the quarter ending September 30, 2025, a decrease of -66.67%. This brings the company's revenue in the last twelve months to 7.00M. In the year 2024, Noile-Immune Biotech had annual revenue of 7.00M, down -97.78%.
Revenue
7.00M
Revenue Growth
-97.78%
P/S Ratio
921.71
Revenue / Employee
280.00K
Employees
25
Market Cap
6.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | 97.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| Soiken Holdings | 4.87B |
| MEDINET | 998.00M |
| OncoTherapy Science | 956.00M |
| Chiome Bioscience | 727.99M |
| PRISM BioLab Co.,LTD | 677.33M |
| Carna Biosciences | 544.45M |